WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
38.74
+0.94 (2.49%)
Jul 31, 2026, 4:08 PM HKT

WuXi Biologics Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
4,9083,3563,4004,4203,388
Depreciation & Amortization
1,4481,4371,169800.67481.78
Other Amortization
29.9824.43-73.8832.3690.49
Loss (Gain) From Sale of Assets
634.68-0.463.4819.270.87
Loss (Gain) From Sale of Investments
-1,04591.72-13.83-379.44-665.44
Stock-Based Compensation
955.061,2161,2741,234531.92
Provision & Write-off of Bad Debts
205.33151.78319.97258.53156.67
Other Operating Activities
935.66-258.43-514.84130.08409.82
Change in Accounts Receivable
-2,590161.93-1,038-1,500-1,441
Change in Inventory
6.39201.85442.46-498.12-783.19
Change in Accounts Payable
797.37375.38-162.34-509.02741.85
Change in Unearned Revenue
410.38-1,313-317.21,6331,071
Change in Other Net Operating Assets
-355.53-226.69178.41-100.14-551.77
Operating Cash Flow
6,3415,2174,6685,5423,431
Operating Cash Flow Growth
21.54%11.77%-15.77%61.51%82.39%

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,685-3,930-4,046-5,868-6,508
Sale of Property, Plant & Equipment
4,17787.33196.8620.1380.86
Cash Acquisitions
----131.49-2,181
Sale (Purchase) of Intangibles
-50.6--10--
Investment in Securities
-3,952-387.97596.39-253.24-1,428
Other Investing Activities
423.07288.5634.07324.74433.9
Investing Cash Flow
-3,087-3,942-3,228-5,908-9,602

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
1,1221,1291,0972,389675.28
Total Debt Issued
1,1221,1291,0972,389675.28
Long-Term Debt Repaid
-2,901-818.68-1,916-2,684-822.11
Total Debt Repaid
-2,901-818.68-1,916-2,684-822.11
Net Debt Issued (Repaid)
-1,779309.96-818.45-295.02-146.83
Issuance of Common Stock
163.0719.3926.1636.1811,035
Repurchase of Common Stock
-1,577-1,766-916.92-2,804-2,517
Other Financing Activities
1,029-1,3143,670471.7-161.91
Financing Cash Flow
-2,164-2,7501,961-2,5928,209

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-155.2183.98-125.99350.11-131.5
Net Cash Flow
934.6-1,3913,275-2,6081,908

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
2,6561,288622.14-326.72-3,077
Free Cash Flow Growth
106.25%106.97%---
Free Cash Flow Margin
12.19%6.89%3.65%-2.14%-29.90%
Free Cash Flow Per Share
0.640.300.14-0.07-0.70
Levered Free Cash Flow
4,284-2,296-320.31-594.39-3,720
Unlevered Free Cash Flow
4,373-2,198-221.25-554.16-3,696

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
159.57200.61217.28108.2483.2
Cash Income Tax Paid
1,4001,092782.53585.66349.99
Change in Working Capital
-1,731-800.5-896.35-974.47-963.33